SEC EDGARJUN 23 min read$CORT

BELANOFF JOSEPH K sold $895K of CORT (indirect holdings)

BELANOFF JOSEPH K (Chief Executive Officer) sold 12,837 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $69.74 ($0.90M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · BELANOFF JOSEPH K

Published Jun 2, 2026, 8:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CORT

Neutral

medium confidence

Mentioned

$CORT

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORTNeutralLow

Why it matters

The disclosure can influence short-term sentiment, but it is not a fundamental catalyst by itself.

Market read

Traders may monitor for follow-on insider activity, but this single 10b5-1 sale provides limited new information.

What to watch

The filing does not disclose reasons for the sale beyond the plan; without accompanying buys or fundamental updates, directional trading edge is limited.

Relevance 6/10Novelty 3/10Timing: Filed after-hours (2026-06-02) for a sale executed 2026-06-01

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO with a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORTNeutralMedium confidence

Context

Corcept Therapeutics CEO Joseph K. Belanoff sold 12,837 shares in an open-market transaction disclosed on Form 4.

Expected impact

Limited, likely sentiment-only drift; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is an ownership-change disclosure (insider sale) with a stated pre-arranged Rule 10b5-1 plan, reducing the likelihood of immediate fundamental information.

Market effects

Sector

Minimal; this is company-specific insider activity without new clinical/regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact may fade quickly.

Key entities

issuer
CORCEPT THERAPEUTICS INC
Subject of the Form 4 insider transaction disclosure.
insider
BELANOFF JOSEPH K
CEO and director who sold shares under a 10b5-1 plan.

Read at source ← All news

SEP 22

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min

SEP 19

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min

SEP 18

$CORTMedAI 8/10

Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) announced that the EMA's CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer, based on Phase 2 and 3 trial data showing improved survival rates. The European Commission will decide by Q4 2026. CORT's stock closed at $114.86, up 2.73%, and was at $115.45 in premarket trading.

rttnews.com2 min

SEP 18

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min

AUG 6

$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min

JUL 31

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min